



PATENT
Docket No. 290.0010 0101

Handwritten initials and date: 2/11/01

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Michael S. Kinch)
Serial No.: 09/640,935)
Filed: August 17, 2000)
For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER
(As Amended)

Group Art Unit: 1623
Examiner: Unknown

TECH CENTER 1600/2900
FEB 20 2001

RECEIVED

INFORMATION DISCLOSURE STATEMENT

Assistant Commissioner for Patents
Washington D.C. 20231

Sir:

In compliance with the duty imposed by 37 C.F.R. § 1.56, and in accordance with C.F.R. §§ 1.97 *et. seq.*, the materials enclosed herewith are brought to the attention of the Examiner as possibly being of interest in connection with the above-identified patent application.

Enclosed are copies of six documents cited in an International Search Report which are not already of record in the present matter, as well as a copy of the International Search Report for the PCT Application Serial No. PCT/US00/22670. Also enclosed herewith are copies of other documents which Applicant brings to the Examiner's attention as possibly being of interest in connection with the above-identified patent application. Consideration of each of the documents is respectfully requested. Pursuant to the provisions of MPEP §609, Applicant further requests that a copy of the 1449 form(s), marked as being considered and initialed by the Examiner, be returned with the next Official Communication.

Co-pending U.S. Applications

Applicants also wish to bring the Examiner's attention to co-pending U.S. Application Serial No. 09/640,952, entitled ANTIBODIES AS A CANCER DIAGNOSTIC, filed August 17, 2000 and co-pending U.S. Application Serial No. 60/232/302, entitled EphA2

Information Disclosure Statement

Page 2

Serial No.: 09/640,935

Filed: August 17, 2000

For: EPHA2 AS A THERAPEUTIC TARGET FOR METASTATIC CANCER (As Amended)

Monoclonal Antibodies and Methods, filed September 12, 2000. Copies of the two co-pending U.S. Applications are enclosed.

It is believed that no fee is due, as this Information Disclosure Statement is filed prior to the receipt of any Action on the merits. However, in the event a fee is due, please charge any fee or credit any overpayment to Account No. 13-4895.

CERTIFICATE UNDER 37 C.F.R. 1.8:

Pursuant to 37 C.F.R. 1.10, I verify that this application is being deposited on this 14th day of February 2001 with the United States Postal Service "Express Mail Post Office to Addressee" service addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231. "Express Mail" mailing label number: EL 776902517 US.

Kimberly A. Hayes
Kimberly A. Hayes

14 February 2001
Date

Respectfully submitted,
Michael S. Kinch
By their Representatives,
Mueting, Raasch & Gebhardt, P.A.
P.O. Box 581415
Minneapolis, MN 55458-1415
Phone: (612)305-1220
Facsimile: (612)305-1228
Customer Number 26813

By: Victoria A. Sandberg
Victoria A. Sandberg
Reg. No. 41,287
Direct Dial (612)305-1226